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Editorial on the Research Topic
Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
In human cells, three RAS genes, named HRAS, KRAS, and NRAS, encode four highly homologous
small GTPases (H-RAS, K-RAS4A, K-RAS4B, and N-RAS). Gain-of-function mutations occur
in ∼30% of all human cancers, including non-small cell lung cancer, pancreatic, colorectal and
breast cancer, and are associated with poor clinical prognosis and resistance to treatment. Since
1982, when activated and transforming human RAS genes were discovered, there have been many
unsuccessful attempts to target RAS oncogenes. RAS oncogenes have thus long been considered to
be undruggable.
Approaches to target RAS oncogenes and RAS-driven cancers are underway, all the efforts to
design therapeutics that selectively target the oncogene or its downstream effectors are justified
by the degree to which RAS-driven tumors remain dependent on oncogenic RAS, making it
a crucial target (1). At the clinical level, the complexity and the signaling redundancy of RAS
function and of its downstream pathways have restrained the successful targeting of RAS-mediated
oncogene addiction. Although recent discoveries have generated interest in the development of
KRAS inhibitors either targeting directly mutant KRAS or targeting the crucial steps required for
KRAS activation, these developments can be beneficial only to a small subset of human tumors
(2, 3).
RAS proteins principally localize in close proximity to plasma membrane, which participate
to the transduction of extracellular growth factor-dependent signaling triggering the activation
of different intracellular pathways, such as MAPK and PI3K pathways (4). The lack of functional
redundancy between the 3 different RAS isoforms is due to their distinctive intracellular localization
and redistribution, generating specific compartmentalized signals (5, 6). Oncogenic RAS signaling
establishes cancer hallmark traits that support cancer plasticity, evade immune attack and
enhance cancer cell migration and metastasis (7, 8). Moreover, RAS proteins promote metabolic
reprogramming of tumor cells, shifting them toward an anabolic metabolism necessary to produce
biomass to support their needs (9–12). The specific rewiring depends on the subcellular, cellular,
and tissue environments within which oncogenic RAS operates (13).
This Research Topic entitled “Oncogenic RAS-dependent reprogramming of cellular plasticity”
aimed to contribute to a better understanding of oncogenic RAS signaling in several traits of cancer
hallmarks, which are the basis of the reprogramming of cancer cells. The published original research
and review articles are briefly described below:
- Muñoz-Maldonado et al. focused on the differences of individual RAS-mutated variants related
to signaling and phenotype, as well as on transcriptomics, proteomics, andmetabolomics profiles
and discussed the association of these mutations with particular therapeutic patient outcomes.
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- Galiè reviewed the studies that explored the controversial role
of Ras proteins and their mutational status in breast cancer,
revealing their role as supporting actors.
- Gimple and Wang reviewed the role of oncogenic RAS
and its downstream effectors in different cancer types and
grades, focusing on the new strategy of targeting RAS recently
emerged and their therapeutic potential.
- Arner et al. reviewed the role of KRAS signaling in epithelial-
to-mesenchymal transition (EMT) and cellular plasticity, and
discussed the contribution of cellular plasticity in cancer
progression, metastasis, and therapy resistance.
- Yang et al. reviewed the recent advances in KRAS-mutant
lung cancer with a particular focus on mechanistic
insights into tumor heterogeneity, clinic implications, and
new therapies.
- Roncarati et al. reviewed the role of microRNAs in
RAS oncogenic activation in human cancers, resulting
to a potentially useful approach to control RAS
oncogenic activation.
- Maffeis et al. reviewed the role of RAS in colorectal cancer and
its link with cellular plasticity, invasion, and migration at both
molecular and morphological levels.
- Nussinov et al. reviewed the mechanisms through which
oncogenic RAS activates its effectors MAPK (Raf/MEK/ERK)
and PI3K (PI3K/Akt/mTOR), shedding light on the
implications for their pharmacological targeting.
- Pupo et al. reviewed the interplay between KRAS and
metabolism focusing on metabolic dependencies of mutant
KRAS-driven lung and pancreatic cancers that could be
attractive therapeutic targets.
There has been a tremendous progress in the understanding
of the genetic architecture, the biological heterogeneity, and
the distinct molecular pathways driven by RAS oncogenes
that raised new hopes for personalized cancer treatment.
More extensive understanding of the RAS pathway in
human cancer will guide the future development of
precision therapies.
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